CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
SAP +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03674281
NCT03674281N/ACompleted

The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System

University of Virginia·interventional·Posted Sep 17, 2018·Updated Jan 12, 2021

In Brief

A clinical study evaluating SAP and CLC for Type 1 Diabetes Mellitus and Cognitive Change. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The objective of this pilot study is (i) to test the use of an Artificial Pancreas (AP) System as a viable therapy treatment for two vulnerable populations: 6 to 10 year-old and adults older ≥65 years old with T1D; (ii) to assess cognitive function in children and older adult patients with T1D and examine whether improved glycemic control defined by stable (more than 70% of the day in glycemic range 70-180 mg/dL) control positively influences cognitive function; and (iii) obtain preliminary data to apply to funds to continue with larger and longer clinical trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 17, 2018
Enrollment StartSep 24, 2018
Primary CompletionNov 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.8 years ago

Interventions

SAPdevice

Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).

CLCdevice

The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.